



Treatable Diabetic Retinopathy Is Extremely Rare Among Pediatric T1D Exchange Clinic Registry Participants

Diabetes Care 2016;39:e218–e219 | DOI: 10.2337/dc16-1691

Giovanna Beauchamp,¹
 Claire T. Boyle,²
 William V. Tamborlane,³
 Kellee M. Miller,² Ingrid M. Libman,⁴
 Michael J. Haller,¹ and Roy W. Beck,²
 for the T1D Exchange Clinic Network

The Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) studies demonstrated that intensive diabetes management provides for marked reduction in risk for diabetic retinopathy (DR) (1,2). Nevertheless, guidelines for DR screening in the post-DCCT era have remained largely unchanged. Current American Diabetes Association guidelines for youth with type 1 diabetes suggest annual eye exams at the start of puberty or at age ≥ 10 years, whichever is earlier, once the youth has had diabetes for 3–5 years (3). We sought to examine how often treatable DR was reported among youth enrolled in the T1D Exchange Clinic Registry (4).

Information about treatment for DR was collected from T1D Exchange Clinic Registry participants via a participant- or parent-completed questionnaire asking, “Have you ever received treatment for diabetic retinopathy (change in the retina of the eye due to diabetes), such as with laser, injections into or around the eye or vitrectomy surgery?” Youth included in the analysis were < 21 years of age and not pregnant.

Of the 12,535 youth included in this analysis (mean age 12 ± 4 years, mean type 1 diabetes duration 5 ± 4 years, 48%

female, mean lifetime average HbA_{1c} $8.6\% \pm 1.4\%$), treatment for DR was self-reported by 45 subjects (0.36%). Notably, of those 45 subjects who reported DR and for whom an ophthalmologist report was available in the medical record ($n = 12$) or for whom treatment history was known ($n = 33$), none (0%) had actually received treatment for DR.

Thus, treated DR is extremely rare in children enrolled in the T1D Exchange Clinic Registry. Our findings support the notion by Huo et al. (5) that screening for DR in all youth with type 1 diabetes solely on the basis of age and diabetes duration may be unjustified. Future studies may indicate that DR screening guidelines can be improved via inclusion of other risk factors such as history of glycemic control, presence of microalbuminuria, hypertension, and dyslipidemia.

The negligible yield of possibly treatable and treated eye lesions compounded by the considerable financial burden associated with eye exams suggests that current guidelines for DR screening in youth with type 1 diabetes may not be cost-effective. While additional studies are needed before firm recommendations can be made, liberalization of pediatric DR screening guidelines may be justified and could allow for utilization of saved resources in areas historically

lacking support such as mental health and nutrition counseling. Formal studies utilizing longitudinal collection of retinal photographs are required to provide the requisite data to confirm the frequency of treatable eye disease and the impact of less rigorous screening frequency.

Acknowledgments. The authors thank the thousands of patients and families who have contributed to the T1D Exchange Clinic Registry, as well as the numerous investigators involved.

Funding. The T1D Exchange Clinic Registry is supported through the Leona M. and Harry B. Helmsley Charitable Trust.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. G.B. contributed to data interpretation and wrote and edited the manuscript. C.T.B. performed statistical analyses and wrote and edited the manuscript. W.V.T., K.M.M., I.M.L., M.J.H., and R.W.B. contributed to data interpretation and reviewed and edited the manuscript. R.W.B. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329: 977–986

¹University of Florida, Gainesville, FL

²Jaeb Center for Health Research, Tampa, FL

³Yale School of Medicine, New Haven, CT

⁴Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA

Corresponding author: Claire T. Boyle, t1dstats6@jaeb.org.

Received 5 August 2016 and accepted 25 September 2016.

© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

2. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *JAMA* 2002;287:2563–2569
3. American Diabetes Association. Microvascular complications and foot care. Sec. 9. In *Standards of Medical Care in Diabetes—2016*. *Diabetes Care* 2016;39(Suppl. 1):S72–S80
4. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange Clinic Registry. *J Clin Endocrinol Metab* 2012;97:4383–4389
5. Huo B, Steffen AT, Swan K, Sikes K, Weinzimer SA, Tamborlane WV. Clinical outcomes and cost-effectiveness of retinopathy screening in youth with type 1 diabetes. *Diabetes Care* 2007;30:362–363